Emergence Therapeutics

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugate (ADC) immunotherapies to treat high-need cancers. Our lead program employs innovative antibody design along with state-of-the-art linker and payload technologies to target Nectin-4 – a significant and well-validated broad-spectrum cancer target.